Biperiden HCl
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Biperiden HCl是抗胆碱能药物[1]。
作为抗胆碱能药物,biperiden首先应用在帕金森氏病的治疗。它是毒蕈碱受体的竞争性拮抗剂。在PD病人中,胞内的多巴胺浓度减少导致多巴胺能和胆碱能神经途径之间的相对失衡。Biperiden HCl可通过降低纹状体乙酰胆碱介导的神经传递来纠正这种失衡现象。Biperiden HCl也用于治疗抗精神病药引发的副作用。另外,临床研究表明,滥用biperiden HCl可造成精神错乱[1, 2]。
参考文献:?
[1] Brocks D R. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci, 1999, 2(2): 39-46.
[2] Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden Dependence: Case Report and Literature Review. Case reports in psychiatry, 2012, 2012.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 347.92 |
Cas No. | 1235-82-1 |
Formula | C21H30ClNO |
Solubility | insoluble in H2O; ≥8.27 mg/mL in EtOH with ultrasonic; ≥8.7 mg/mL in DMSO |
Chemical Name | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride |
SDF | Download SDF |
Canonical SMILES | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
动物实验: | |
动物模型 |
雄性Lister Hooded大鼠模型; |
剂量 |
3和10 mg / kg,腹腔注射,90分钟;或4 mg,口服给药 |
应用 |
Biperiden HCl在大鼠中作为认知损伤诱导剂,Biperiden(10mg/kg)诱导副作用,使得大鼠花费更多的时间执行任务 [1]。 此外,口服剂量4mg的Biperiden HCl能达到的最高血药浓度值约4ng/mL [2]。 |
注意事项 |
请于室内测试所有化合物的溶解度。实际溶解度和理论值可能略有不同,这是由实验系统的误差引起的,属于正常现象。 |
References: 1. Szczodry, O., van der Staay, F. J. and Arndt, S. S. (2014) Modelling Alzheimer-like cognitive deficits in rats using biperiden as putative cognition impairer. Behav Brain Res. 274, 307-311 2. Brocks, D. R. (1999) Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 2, 39-46 |
质量控制和MSDS
- 批次: